Adial Pharmaceuticals announced a collaboration with Boudicca Dx, a global precision medicine testing accelerator. Under the agreement, Boudicca will support Adial in advancing its technical and regulatory strategy for the Company’s companion diagnostic genetic test, to ensure it is validated both technically and clinically per FDA guidelines as part of Adial’s regulatory strategy for its lead investigational asset, AD04, a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder. Adial’s companion diagnostic is intended to accompany AD04 in identifying potential patients, including recruitment for the Company’s planned Phase 3 program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04
- Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
- Adial Pharmaceuticals announces last patient dosed in PK study of AD04
- Adial Pharmaceuticals files new patent application to protect core assets
- Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044